CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Income Statement [Abstract]
Net revenues	$ 101,828	$ 73,309	$ 351,318
Cost of revenues	24,496	19,814	88,606
Gross profit	77,332	53,495	262,712
Operating costs and expenses:
Research, development and clinical trials	25,271	17,042	79,003
Sales and marketing	28,834	22,333	96,675
General and administrative	26,608	20,238	87,948
Total operating costs and expenses	80,713	59,613	263,626
Operating income (loss)	(3,381)	(6,118)	(914)
Financial expenses (income), net	2,432	2,371	7,910
Income (loss) before income tax	(5,813)	(8,489)	(8,824)
Income tax	(9,765)	3,661	(1,594)
Net income (loss)	$ 3,952	$ (12,150)	$ (7,230)
Basic net income (loss) per ordinary share (in usd per share)	$ 0.04	$ (0.13)	$ (0.07)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	99,877,567	94,811,282	97,237,549
Diluted net income (loss) per ordinary share (in usd per share)	$ 0.04	$ (0.13)	$ (0.07)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	108,100,623	94,811,282	97,237,549